Nubad LLC
Greer, SC
- UEI
- ENA5G1N2MWP4
- CAGE
- 5M2Z2
- Primary NAICS
- 541380 Testing Laboratories and Services
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Other
- SAM.gov registration date
- Physical address
- 209 Riverside Ct a, Greer, SC 29650, USA
- Website
- nubadllc.com
- Founded
- 2009
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Curza Inc. | Salt Lake City, UT | — |
| Quercus Molecular Design, LLC | Avon, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Novobiotic Pharmaceuticals, LLC | Cambridge, MA | 238990 All Other Specialty Trade Contractors |
| Crestone, Inc. | Boulder, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| 3 Point Bio LLC | Boxford, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Nubad LLC is a for-profit limited liability company focused on developing novel therapeutics for drug-resistant infections. Through federal grants from the National Institutes of Health, Nubad conducts research to identify new classes of antibiotics and screening assays targeting conserved bacterial genes and structures.
Specifically, Nubad has received over $20 million in federal grant funding to develop aminoglycosides, peptide nucleic acids, and biophysical screening assays with reduced toxicity, as well as COVID-19 and gene silencing therapeutics. Major funding has come from the National Institute of Allergy and Infectious Diseases Allergy and Infectious Diseases Research and Research Project Grant programs. Nubad's grants have focused on targeting bacterial resistance, protein synthesis inhibition, and toxicity reduction pathways. This includes developing aminoglycosides, peptide nucleic acids, and screening assays to identify leads against multidrug-resistant infections like carbapenem-resistant Enterobacteriaceae. Nubad has also received grants to develop therapeutics targeting SARS-CoV-2 and therapies using miRNA gene silencing. Partners have included academic institutions and small businesses collaborating on assay development and testing.
Quick answers
Is Nubad LLC registered in SAM.gov?
Yes. Nubad LLC's SAM.gov registration is active through September 29, 2027.
What is Nubad LLC's most recent federal award?
Nubad LLC's most recent federal grant award is Ototoxicity of modified aminoglycosides (R44AI172739), from National Institute of Allergy and Infectious Diseases (NIH), on July 11, 2022.
On GovTribe
See Nubad LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors